^Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL (Aug 1996). "A receptor subtype involved in neuropeptide-Y-induced food intake". Nature382 (6587): 168–71. doi:10.1038/382168a0. PMID8700207.
^Lutz CM, Richards JE, Scott KL, Sinha S, Yang-Feng TL, Frankel WN, Thompson DA (Feb 1998). "Neuropeptide Y receptor genes mapped in human and mouse: receptors with high affinity for pancreatic polypeptide are not clustered with receptors specific for neuropeptide Y and peptide YY". Genomics46 (2): 287–90. doi:10.1006/geno.1997.5024. PMID9417917.
^Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H (May 2006). "Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor". The Journal of Pharmacology and Experimental Therapeutics317 (2): 562–70. doi:10.1124/jpet.105.099705. PMID16436501.
^Walker MW, Wolinsky TD, Jubian V, Chandrasena G, Zhong H, Huang X, Miller S, Hegde LG, Marsteller DA, Marzabadi MR, Papp M, Overstreet DH, Gerald CP, Craig DA (March 2009). "The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 (N-([trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl)-methanesulfonamide) exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity". The Journal of Pharmacology and Experimental Therapeutics328 (3): 900–11. doi:10.1124/jpet.108.144634. PMID19098165.
"Neuropeptide Y Receptors: Y5". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
Further reading
Parker E, Van Heek M, Stamford A (2002). "Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status.". Eur. J. Pharmacol.440 (2–3): 173–87. doi:10.1016/S0014-2999(02)01427-9. PMID12007534.
Hu Y, Bloomquist BT, Cornfield LJ, et al. (1996). "Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior". J. Biol. Chem.271 (42): 26315–9. doi:10.1074/jbc.271.42.26315. PMID8824284.
Herzog H, Darby K, Ball H, et al. (1997). "Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation". Genomics41 (3): 315–9. doi:10.1006/geno.1997.4684. PMID9169127.
Nichol KA, Morey A, Couzens MH, et al. (1999). "Conservation of expression of neuropeptide Y5 receptor between human and rat hypothalamus and limbic regions suggests an integral role in central neuroendocrine control". J. Neurosci.19 (23): 10295–304. PMID10575027.
Berglund MM, Schober DA, Statnick MA, et al. (2003). "The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction". J. Pharmacol. Exp. Ther.306 (1): 147–56. doi:10.1124/jpet.103.051227. PMID12665544.
Beauverger P, Rodriguez M, Nicolas JP, et al. (2005). "Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay". Cell. Signal.17 (4): 489–96. doi:10.1016/j.cellsig.2004.09.006. PMID15601626.
Movafagh S, Hobson JP, Spiegel S, et al. (2006). "Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors". FASEB J.20 (11): 1924–6. doi:10.1096/fj.05-4770fje. PMID16891622.
Coletta DK, Schneider J, Stern MP, et al. (2007). "Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans". Obesity (Silver Spring, Md.)15 (4): 809–15. doi:10.1038/oby.2007.610. PMID17426313.